|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00005487 |
Purpose
To conduct a prospective observational study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced signs and symptoms) that predict progression to clinically overt cardiovascular disease in a diverse and representative population-based sample of men and women aged 35-84. Specifically the study shall: determine characteristics related to progression of subclinical to clinical cardiovascular disease; identify factors related to newer measures of subclinical disease and examine relationship of new to established measures; and develop population-based methods, suitable for application in future screening and intervention studies, for identifying asymptomatic persons at highest risk of clinical events.
| Condition | Phase |
|---|---|
|
Atherosclerosis Cardiovascular Diseases Heart Diseases Coronary Artery Disease Coronary Disease Stroke Myocardial Infarction Heart Failure Diabetes Mellitus, Type 2 Hypertension Diabetes Mellitus |
N/A |
| Study Type: | Observational |
| Study Design: | Cohort, Prospective |
| Official Title: | Multi-Ethnic Study of Atherosclerosis (MESA) |
| Estimated Enrollment: | 6000 |
| Study Start Date: | January 1999 |
| Estimated Study Completion Date: | August 2015 |
| Estimated Primary Completion Date: | August 2015 (Final data collection date for primary outcome measure) |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 45 Years to 84 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Participants were recruited from the MESA Study Field Centers.
No eligibility criteria
Contacts and Locations| Principal Investigator: | David Bluemke | Johns Hopkins University |
| Principal Investigator: | Gregory Burke | Wake Forest University |
| Principal Investigator: | Aaron Folsom | University of Minnesota |
| Principal Investigator: | Richard Kronmal | University of Washington |
| Principal Investigator: | Kiang Liu | Northwestern University |
| Principal Investigator: | Daniel O'Leary | New England Medical Center Hospitals |
| Principal Investigator: | Steven Shea | Columbia University |
| Principal Investigator: | Moyses Szklo | Johns Hopkins University |
| Principal Investigator: | Russell Tracy | University of Vermont |
| Principal Investigator: | Matthew Budoff | Los Angeles Biomedical Research Institute |
| Principal Investigator: | Karol Watson | University of California, Los Angeles |
More Information
| Responsible Party: | University of Washington Coordinating Center ( Richard A. Kronmal, PhD ) |
| Study ID Numbers: | 5003 |
| Study First Received: | May 25, 2000 |
| Last Updated: | January 31, 2008 |
| ClinicalTrials.gov Identifier: | NCT00005487 History of Changes |
| Health Authority: | United States: Federal Government |
|
Coronary Arteriosclerosis Cerebrovascular Accident Heart Failure, Congestive Diabetes Mellitus, Non-Insulin Dependent |
|
Atherosclerosis Arterial Occlusive Diseases Heart Failure Metabolic Diseases Heart Diseases Myocardial Ischemia Vascular Diseases Diabetes Mellitus Endocrine System Diseases Ischemia Arteriosclerosis |
Coronary Disease Necrosis Pathologic Processes Diabetes Mellitus, Type 2 Cardiovascular Diseases Glucose Metabolism Disorders Infarction Myocardial Infarction Coronary Artery Disease Hypertension |